Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.

Author: AllolioBruno, ArltWiebke, BertagnaXavier, BertheratJérôme, BeuschleinFelix, ChortisVasileios, FassnachtMartin, HahnerStefanie, HughesBeverly A, KaravitakiNiki, LibéRossella, MannelliMassimo, ManteroFranco, NightingalePeter, O'NeilDonna M, OpocherGiuseppe, PorfiriEmilio, QuinklerMarcus, SchneiderPetra, ShackletonCedric H L, SherlockMark, StewartPaul M, TaylorAngela E, TerzoloMassimo, TomlinsonJeremy W

Paper Details 
Original Abstract of the Article :
Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is considered an adrenolytic substance, but ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1210/jc.2012-2851

データ提供:米国国立医学図書館(NLM)

Mitotane Therapy in Adrenocortical Cancer: Unveiling Steroidogenic Effects

Adrenocortical cancer is a rare but aggressive cancer that affects the adrenal glands. Mitotane is a medication used to treat this cancer, but it can have significant side effects, including adrenal insufficiency and male hypogonadism. This research explores the specific effects of mitotane on steroidogenesis, providing valuable insights into the mechanisms underlying these side effects.

Unraveling the Steroidogenic Effects of Mitotane

This study investigated the specific effects of mitotane on steroidogenesis, the process of hormone production in the adrenal glands. The researchers found that mitotane induces CYP3A4, an enzyme involved in steroid metabolism, and inhibits 5α-reductase, an enzyme involved in androgen production. These findings help explain the development of adrenal insufficiency and male hypogonadism in patients treated with mitotane.

Personalized Management of Mitotane Therapy

This research underscores the importance of personalized management of mitotane therapy. By understanding the specific steroidogenic effects of mitotane, clinicians can better tailor treatment plans to address potential side effects. Just as a camel adapts to the different challenges of the desert, healthcare professionals must adjust their approach based on the individual needs of their patients.

Dr.Camel's Conclusion

This research is like a guidebook through the desert of adrenocortical cancer treatment. By understanding the specific effects of mitotane on steroidogenesis, we can better navigate the challenges of this complex condition and provide personalized care for our patients.
Date :
  1. Date Completed 2013-03-07
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

23162091

DOI: Digital Object Identifier

10.1210/jc.2012-2851

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.